Using detailed spatial molecular analysis of human NSCLC cohorts and functional in vitro studies, we demonstrate the dominant effect of cancer cell TAP2 downregulation in tumor immune evasion and immunotherapy resistance. The gene discussed is TAP2; the disease is non-small cell lung carcinoma.